CD34 and neoplasm: The tumor volume was calculated and is shown in Figure 3D. Additionally, CD34 (an endothelial cell marker) expression was also decreased in the 4AAQB-treated group in comparison to that in the vehicle group (Figure 3E), revealing the antiangiogenic activities of 4AAQB.